{"filing":{"accession_number":"0001640334-26-001258","cik":"0001348362","ticker":"LEXX","company_name":"Lexaria Bioscience Corp.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-29","primary_document":"lxrp_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033426001258/lxrp_8k.htm"},"events":[{"id":22689,"run_id":20526,"accession_number":"0001640334-26-001258","anchor_item_number":"3.03","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"summary":"Lexaria Bioscience effected a 1-for-15 reverse stock split to restore compliance with NASDAQ Capital Market's minimum $1.00 bid price requirement under Listing Rule 5550(a)(2), addressing delisting risk during its 180-day compliance period. The company anticipates requesting a NASDAQ hearing to appeal any delisting notification.","company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":22708,"accession_number":"0001640334-26-001258","item_number":"3.03","item_title":"Material Modification to Rights of Security Holders","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The filing discloses a 1-for-15 reverse stock split effected primarily \"to enable the Company to expeditiously restore compliance with the continued listing standard of NASDAQ Capital Market\" and specifically to address the \"minimum $1.00 bid price per share requirement of Nasdaq Listing Rule 5550(a)(2).\" The company explicitly states it is \"in proactively performing this Reverse Split contemporaneous with the end of our 180-day compliance period\" and \"anticipate requesting the required Nasdaq hearing to appeal any delisting notification.\" This is a material disclosure of delisting risk and the company's remedial action to avoid it.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:18:14.836191+00:00","company_name":"","ticker":null,"filing_date":""},{"id":22709,"accession_number":"0001640334-26-001258","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The filing discloses a reverse stock split (1-for-15) undertaken specifically to regain compliance with NASDAQ's minimum $1.00 bid price requirement under Listing Rule 5550(a)(2). The press release explicitly states the \"primary goal\" is to achieve compliance and references the company's \"180-day compliance period\" and anticipated appeal of \"any delisting notification.\" This is a direct response to delisting risk, making it the material event at the core of the disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:18:14.836191+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":22708,"accession_number":"0001640334-26-001258","item_number":"3.03","item_title":"Material Modification to Rights of Security Holders","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The filing discloses a 1-for-15 reverse stock split effected primarily \"to enable the Company to expeditiously restore compliance with the continued listing standard of NASDAQ Capital Market\" and specifically to address the \"minimum $1.00 bid price per share requirement of Nasdaq Listing Rule 5550(a)(2).\" The company explicitly states it is \"in proactively performing this Reverse Split contemporaneous with the end of our 180-day compliance period\" and \"anticipate requesting the required Nasdaq hearing to appeal any delisting notification.\" This is a material disclosure of delisting risk and the company's remedial action to avoid it.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:18:14.836191+00:00","company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","filing_date":"2026-07-30"},{"id":22709,"accession_number":"0001640334-26-001258","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"The filing discloses a reverse stock split (1-for-15) undertaken specifically to regain compliance with NASDAQ's minimum $1.00 bid price requirement under Listing Rule 5550(a)(2). The press release explicitly states the \"primary goal\" is to achieve compliance and references the company's \"180-day compliance period\" and anticipated appeal of \"any delisting notification.\" This is a direct response to delisting risk, making it the material event at the core of the disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-02T02:18:14.836191+00:00","company_name":"Lexaria Bioscience Corp.","ticker":"LEXX","filing_date":"2026-07-30"}]}